Poolbeg Pharma (POLB) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Nov 2022 01:51 PM
EQS
Poolbeg Pharma makes virus 'breakthrough' using...
08 Nov 2022 07:00 AM
RNS
AI programme yields novel RSV drug targets
21 Oct 2022 07:00 AM
RNS
Upcoming events participation
06 Oct 2022 04:40 PM
RNS
Second Price Monitoring Extn
06 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
06 Oct 2022 07:00 AM
RNS
CEO Share Purchase
04 Oct 2022 07:00 AM
RNS
POLB 001 US Patent update
21 Sep 2022 07:00 AM
RNS
Poolbeg licence of Melioidosis vaccine candidate
12 Sep 2022 07:00 AM
RNS
HC Wainwright Global Investment Conference
06 Sep 2022 02:05 PM
RNS
Second Price Monitoring Extn
06 Sep 2022 02:00 PM
RNS
Price Monitoring Extension
06 Sep 2022 07:00 AM
RNS
Interim Results
31 Aug 2022 07:25 AM
RNS
Notice of Results
29 Jul 2022 07:00 AM
RNS
Appointment of Joint Broker
20 Jul 2022 07:00 AM
RNS
POLB001 human challenge clinical trial to commence
12 Jul 2022 02:06 PM
RNS
Second Price Monitoring Extn
12 Jul 2022 02:00 PM
RNS
Price Monitoring Extension
27 Jun 2022 07:00 AM
RNS
Project update for AI model of RSV data
21 Jun 2022 04:40 PM
RNS
Second Price Monitoring Extn
21 Jun 2022 04:36 PM
RNS
Price Monitoring Extension
26 May 2022 02:05 PM
RNS
Second Price Monitoring Extn
26 May 2022 02:00 PM
RNS
Price Monitoring Extension
26 May 2022 07:00 AM
RNS
US patents granted for POLB 001 and POLB 002
25 May 2022 04:40 PM
RNS
Second Price Monitoring Extn
25 May 2022 04:35 PM
RNS
Price Monitoring Extension
23 May 2022 01:01 PM
RNS
TR-1: Notification of major interest in shares
12 May 2022 07:00 AM
RNS
GMP manufacturing contract signed
11 May 2022 07:00 AM
RNS
Attendance at European Melioidosis Congress
27 Apr 2022 07:00 AM
RNS
Distribution in Specie update
14 Apr 2022 07:00 AM
RNS
Key POLB 002 European Patent Granted
11 Apr 2022 07:00 AM
RNS
Distribution in Specie Shareholders
04 Apr 2022 12:26 PM
RNS
Result of AGM
31 Mar 2022 07:00 AM
RNS
POLB001 Update - Clinical Trial Agreement Signed
30 Mar 2022 07:00 AM
RNS
Commencement of trading on US OTCQB market
24 Mar 2022 07:00 AM
RNS
AI deal signed with CytoReason
09 Mar 2022 07:00 AM
RNS
Notice of AGM
03 Mar 2022 07:00 AM
RNS
Final Results
28 Feb 2022 07:00 AM
RNS
Notice of Results
24 Feb 2022 07:00 AM
RNS
Artificial Intelligence deal with OneThree Biotech
31 Jan 2022 07:00 AM
RNS
Confirmation of vaccine platform licence execution
17 Jan 2022 07:00 AM
RNS
Exclusive license of RNA-based immunotherapy asset
16 Dec 2021 07:00 AM
RNS
Poolbeg to develop oral vaccine delivery platform
06 Dec 2021 07:00 AM
RNS
Poolbeg signs option for new vaccine candidate
25 Nov 2021 07:00 AM
RNS
Scientific Advisory Board Appointment
18 Nov 2021 07:00 AM
RNS
Update on POLB 001 Clinical Development
14 Oct 2021 09:05 AM
RNS
Second Price Monitoring Extn
14 Oct 2021 09:00 AM
RNS
Price Monitoring Extension
14 Oct 2021 07:00 AM
RNS
PredictViral Patent Update
07 Oct 2021 07:00 AM
RNS
RNA sequencing ahead of AI analysis programme
13 Sep 2021 07:00 AM
RNS
September and October Investor conferences
UK 100

Latest directors dealings